questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Antigènes B7
Antigène CD274
Antigène CD274 : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD274 : Questions médicales les plus fréquentes",
"headline": "Antigène CD274 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD274 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2025-05-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD274"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes B7",
"url": "https://questionsmedicales.fr/mesh/D060887",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes B7",
"code": {
"@type": "MedicalCode",
"code": "D060887",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.168"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD274",
"alternateName": "B7-H1 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D060890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Soldano Ferrone",
"url": "https://questionsmedicales.fr/author/Soldano%20Ferrone",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Haidong Dong",
"url": "https://questionsmedicales.fr/author/Haidong%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Hongwei Du",
"url": "https://questionsmedicales.fr/author/Hongwei%20Du",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Barbara Savoldo",
"url": "https://questionsmedicales.fr/author/Barbara%20Savoldo",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Gianpietro Dotti",
"url": "https://questionsmedicales.fr/author/Gianpietro%20Dotti",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36159778",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.omto.2022.08.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.",
"datePublished": "2024-04-15",
"url": "https://questionsmedicales.fr/article/38627145",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vaccine.2024.04.037"
}
},
{
"@type": "ScholarlyArticle",
"name": "Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention.",
"datePublished": "2022-05-28",
"url": "https://questionsmedicales.fr/article/35636504",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jid.2022.04.029"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.",
"datePublished": "2022-11-14",
"url": "https://questionsmedicales.fr/article/36396553",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcyt.2022.10.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.",
"datePublished": "2024-10-30",
"url": "https://questionsmedicales.fr/article/39481241",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vaccine.2024.126463"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes B7",
"item": "https://questionsmedicales.fr/mesh/D060887"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène CD274",
"item": "https://questionsmedicales.fr/mesh/D060890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD274 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD274",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD274",
"description": "Comment diagnostiquer une expression anormale de CD274 ?\nQuels tests sanguins sont utilisés pour CD274 ?\nCD274 est-il associé à des biomarqueurs spécifiques ?\nQuels types de cancers montrent une surexpression de CD274 ?\nComment évaluer l'impact de CD274 sur le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD274",
"description": "Quels symptômes sont liés à une surexpression de CD274 ?\nCD274 influence-t-il les symptômes des maladies auto-immunes ?\nY a-t-il des symptômes spécifiques au cancer liés à CD274 ?\nComment CD274 affecte-t-il la réponse aux infections ?\nLes symptômes de CD274 sont-ils visibles cliniquement ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD274",
"description": "Peut-on prévenir l'expression de CD274 ?\nComment un mode de vie sain influence-t-il CD274 ?\nY a-t-il des vaccins ciblant CD274 ?\nLa détection précoce des cancers aide-t-elle à gérer CD274 ?\nLes habitudes alimentaires influencent-elles CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD274",
"description": "Quels traitements ciblent CD274 ?\nComment les thérapies immunologiques agissent-elles sur CD274 ?\nCD274 peut-il être une cible pour la thérapie génique ?\nQuels effets secondaires sont associés aux traitements ciblant CD274 ?\nLes traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD274",
"description": "Quelles complications sont liées à une surexpression de CD274 ?\nCD274 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de résistance aux traitements avec CD274 ?\nComment CD274 influence-t-il la survie des patients ?\nLes complications de CD274 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD274",
"description": "Quels facteurs augmentent le risque d'expression de CD274 ?\nLe tabagisme influence-t-il CD274 ?\nY a-t-il un lien entre l'obésité et CD274 ?\nLes infections virales affectent-elles CD274 ?\nLe stress chronique influence-t-il CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD274 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour CD274 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274."
}
},
{
"@type": "Question",
"name": "CD274 est-il associé à des biomarqueurs spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1."
}
},
{
"@type": "Question",
"name": "Quels types de cancers montrent une surexpression de CD274 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de CD274 sur le système immunitaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de CD274 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "CD274 influence-t-il les symptômes des maladies auto-immunes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Comment CD274 affecte-t-il la réponse aux infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections."
}
},
{
"@type": "Question",
"name": "Les symptômes de CD274 sont-ils visibles cliniquement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'expression de CD274 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il CD274 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins ciblant CD274 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274."
}
},
{
"@type": "Question",
"name": "La détection précoce des cancers aide-t-elle à gérer CD274 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD274 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CD274 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274."
}
},
{
"@type": "Question",
"name": "Comment les thérapies immunologiques agissent-elles sur CD274 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "CD274 peut-il être une cible pour la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont associés aux traitements ciblant CD274 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations."
}
},
{
"@type": "Question",
"name": "Les traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une surexpression de CD274 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une immunosuppression accrue et une progression tumorale."
}
},
{
"@type": "Question",
"name": "CD274 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements avec CD274 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques."
}
},
{
"@type": "Question",
"name": "Comment CD274 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer."
}
},
{
"@type": "Question",
"name": "Les complications de CD274 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'expression de CD274 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il CD274 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'obésité et CD274 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'obésité peut être associée à une expression accrue de CD274."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles CD274 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il CD274 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire."
}
}
]
}
]
}
B7-H3 (CD276) has emerged as a target for cancer immunotherapy by virtue of consistent expression in many malignancies, relative absence from healthy tissues, and an emerging role as a driver of tumor...
The head domain of the hemagglutinin of influenza viruses plays a dominant role in the antibody response due to the presence of immunodominant antigenic sites that are the main targets of host neutral...
Merkel cell polyomavirus is the causative agent for most Merkel cell carcinomas (MCCs). This highly aggressive skin cancer shows rapid progression, with metastasis being a significant challenge for pa...
Cholangiocarcinoma (CCA) is a lethal bile-duct cancer that is difficult to treat by current standard procedures. This drawback has prompted us to develop adoptive T-cell therapy for CCA, which require...
To overcome this problem, we developed anti-MUC1-CAR T cells containing PD-1-CD28 switch receptor (SR), namely αM.CAR/SR T cells, to target MUC1 and switch on the inhibitory signal of PD-1/PD-L1 inter...
Initially, the upregulations of MUC1 and PD-L1 proteins were confirmed in CCA cell lines. αM.CAR and SR were co-expressed in 53.53 ± 13.89% of transduced T cells, mainly CD8...
Taken together, the cytotoxic function of αM.CAR/SR T cells was enhanced over the αM.CAR T cells, which are potential to be further tested for CCA treatment....
A vaccine effective against both SARS-CoV-2 and influenza A (IAV) viruses could represent a cost-effective strategy to reduce their combined public health burden as well as potential complications ari...
Cutaneous squamous cell carcinoma (CSCC) is the second most common malignant tumor of the skin. B7 homolog 4 (B7-H4) and B7-H5 (B7 homolog 5) are associated with a variety of tumors. Investigate the p...
Malignant neoplasms pose a formidable threat to human well-being. Prior studies have documented the extensive expression of B7 homolog 3 (B7-H3 or CD276) across various tumors, affecting glucose metab...
The Type VI secretion system (T6SS) is a multicomponent apparatus, present in many Gram-negative bacteria, which can inhibit bacterial prey in various ecological niches....
The role of linker H1 histones in plant defence has recently been investigated. Sheikh et al. found that Arabidopsis thaliana plants that were lacking all three H1 proteins showed increased disease re...
B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of B7 family that is aberrantly and consistently expressed in several human cancers, and its overexpression correlates with weak prognosis. B7-H...